Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash & Equivalents (2016 - 2026)

Usana Health Sciences has reported Cash & Equivalents over the past 17 years, most recently at $162.8 million for Q2 2026.

  • Quarterly Cash & Equivalents fell 9.39% to $162.8 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $162.8 million through Apr 2026, down 9.39% year-over-year, with the annual reading at $158.4 million for FY2026, 12.87% down from the prior year.
  • Cash & Equivalents was $162.8 million for Q2 2026 at Usana Health Sciences, up from $158.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $364.9 million in Q3 2024 and troughed at $145.3 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $243.4 million (2022), against an average of $249.0 million.
  • Year-over-year, Cash & Equivalents soared 30.3% in 2023 and then crashed 60.17% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $288.4 million in 2022, then grew by 14.56% to $330.4 million in 2023, then tumbled by 44.99% to $181.8 million in 2024, then dropped by 20.04% to $145.3 million in 2025, then rose by 11.97% to $162.8 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Cash & Equivalents are $162.8 million (Q2 2026), $158.4 million (Q1 2026), and $145.3 million (Q3 2025).